Literature DB >> 18026143

Functional analysis of cytomegalovirus-specific T lymphocytes compared to tetramer assay in patients undergoing hematopoietic stem cell transplantation.

Y Morita-Hoshi1, Y Heike, M Kawakami, T Sugita, O Miura, S-W Kim, S-I Mori, T Fukuda, R Tanosaki, K Tobinai, Y Takaue.   

Abstract

In order to evaluate whether we could predict reactivation of CMV by monitoring the number of CMV-specific cytotoxic T-lymphocytes (CTL), tetramer analysis was performed in 37 patients who underwent hematopoietic stem cell transplantation (HSCT). The results disclosed that the mean number of CMV-specific CTL at day 30 did not differ among patients who developed CMV antigenemia (22/microl) and those who did not (12/microl). Serial tetramer analysis showed that 21% of the patients had >10/microl CMV-specific CTL at the first detection of CMV antigenemia and 67% of the patients had more than 10/microl CMV-specific CTL at the onset of CMV disease. Intracellular staining upon stimulation by CMV lysates and peptide in patients with CMV colitis revealed that both IFN-gamma producing CD4+ and CD8+ lymphocytes were suppressed at the onset of CMV colitis (1.6 and 8/microl), which increased with recovery of the disease (19 and 47/microl). These data suggest that it is difficult to predict CMV reactivation solely by the number of CMV-specific CTL. We suggest that additional functional analysis by intracellular cytokine assay may be useful for immunomonitoring against CMV.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18026143     DOI: 10.1038/sj.bmt.1705932

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  5 in total

1.  Impact of T cell selection methods in the success of clinical adoptive immunotherapy.

Authors:  Natalia Ramírez; Lorea Beloki; Miriam Ciaúrriz; Mercedes Rodríguez-Calvillo; David Escors; Cristina Mansilla; Eva Bandrés; Eduardo Olavarría
Journal:  Cell Mol Life Sci       Date:  2014-04       Impact factor: 9.261

Review 2.  CMV-specific immune reconstitution following allogeneic stem cell transplantation.

Authors:  Emily Blyth; Barbara Withers; Leighton Clancy; David Gottlieb
Journal:  Virulence       Date:  2016-08-09       Impact factor: 5.882

Review 3.  In-depth summary over cytomegalovirus infection in allogeneic hematopoietic stem cell transplantation recipients.

Authors:  Samira Karami; Elham Roshandel; Haniyeh Ghaffari Nazari; Abbas Hajifathali; Farzaneh Tavakoli; Sayeh Parkhideh
Journal:  Virusdisease       Date:  2021-07-28

4.  Vascular dysfunction in young, mid-aged and aged mice with latent cytomegalovirus infections.

Authors:  R B Gombos; J C Brown; J Teefy; R L Gibeault; K L Conn; L M Schang; D G Hemmings
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-11-02       Impact factor: 4.733

5.  The risk of early and late CMV DNAemia associated with Campath use in stem cell transplant recipients.

Authors:  H C Buyck; H G F Prentice; P D Griffiths; V C Emery
Journal:  Bone Marrow Transplant       Date:  2009-12-07       Impact factor: 5.483

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.